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Abstract The devastating inherited disease cystic fibrosis (CF) is caused by mutations of the
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) anion channel. The recent approval
of the CFTR potentiator drug ivacaftor (Vx-770) for the treatment of CF patients has marked the
advent of causative CF therapy. Currently, thousands of patients are being treated with the drug,
and its molecular mechanism of action is under intensive investigation. Here we determine the
solubility profile and true stimulatory potency of Vx-770 towards wild-type (WT) and mutant human
CFTR channels in cell-free patches of membrane. We find that its aqueous solubility is ~200 fold
lower (~60 nanomolar), whereas the potency of its stimulatory effect is >100 fold higher, than
reported, and is unexpectedly fully reversible. Strong, but greatly delayed, channel activation by
picomolar Vx-770 identifies multiple sequential slow steps in the activation pathway. These findings
provide solid guidelines for the design of in vitro studies using Vx-770.
DOI: https://doi.org/10.7554/eLife.46450.001
Introduction
CFTR belongs to the family of ATP Binding Cassette (ABC) proteins (Riordan et al., 1989), and
forms an anion selective channel which is activated by phosphorylation of its cytosolic regulatory (R)
domain by cyclic AMP-dependent protein kinase (PKA) (Berger et al., 1991; Tabcharani et al.,
1991). In phosphorylated CFTR channels opening and closing (gating) of the anion pore is coupled
to conformational changes induced by ATP binding and hydrolysis at two cytosolic nucleotide bind-
ing domains (NBDs) (Anderson et al., 1991; Li et al., 1996). CFTR channels are present in the apical
membrane of epithelial cells that line the lung, intestine, pancreatic duct, and sweat duct, and the
regulated flow of anions, primarily chloride and bicarbonate, through CFTR is indispensable for the
salt-water homeostasis of those epithelia. CF, the most common lethal inherited disease among Cau-
casians, is caused by CFTR mutations which have been classified based on their molecular conse-
quences. Thus, some mutations diminish production (Class I and V), folding/trafficking (Class II), or
stability (Class VI) of the CFTR protein, wheres others impair channel gating (Class III), or anion per-
meation through the open pore (Class IV) (De Boeck and Amaral, 2016). The most common CF
mutation, deletion of phenylalanine 508 (DF508), is present in ~90% of patients and impairs both
channel surface expression (Cheng et al., 1990) and open probability (Miki et al., 2010).
Pharmacotherapy of CF is currently focused on developing compounds that either enhance sur-
face expression (‘correctors’) or stimulate channel gating (‘potentiators’) of mutant CFTR. The poten-
tiator Vx-770 (Van Goor et al., 2009), identified by Vertex Pharmaceuticals using high-throughput
screening, has proven successful and was approved by the FDA for the treatment of patients carry-
ing G551D and other gating mutations (Ramsey et al., 2011). This breakthrough has demonstrated
the feasibility of efficient causative CF therapy using small-molecule potentiators, at least for this
subset of patients (<5% of all CF cases). Moreover, in a recent phase two clinical trial, patients
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carrying the most common CF mutation DF508 also experienced significant clinical improvement
from co-administration of Vx-770 with a combination of corrector drugs (Boyle et al., 2014;
Wainwright et al., 2015; Davies et al., 2018).
Although treatment with Vx-770 (administered orally, either alone or in combination with correc-
tor drugs) is accepted as the standard of care for the majority of CF patients in the US, many of the
basic properties of the drug have remained unexplained or controversial. Thus, CFTR channel stimu-
lation by Vx-770 in cell-free patches is reportedly irreversible (Jih and Hwang, 2013; Lin et al.,
2016; Yeh et al., 2015; Yeh et al., 2017; Wang et al., 2014; Wang et al., 2018), maximal stimula-
tion of WT CFTR channels shows large variability (ranging from ~1.1 fold [Cui and McCarty, 2015]
to ~3 fold [Wang et al., 2018]), and in some studies its acute application caused (Cholon et al.,
2014) – or accentuated (Wang et al., 2014) – CFTR channel inactivation. Vx-770 is routinely used at
concentrations up to 10 mM (Cui and McCarty, 2015; Langron et al., 2018; Liu and Dawson, 2014;
Van Goor et al., 2009; Van Goor et al., 2014; Yu et al., 2012; Wang et al., 2014; Wang et al.,
2018), but data on its aqueous solubility have not yet been published.
Results
Aqueous solubility of Vx-770 is two orders of magnitude lower than
generally assumed
We reasoned that some of the reported controversies on Vx-770 effects might be explained by the
use of highly supersaturated concentrations of the drug in all published studies, and set out to deter-
mine its true solubility profile. Starting from crystalline Vx-770 (Selleck Chemicals), solubilities (S) of
the drug in various organic solvents could be readily determined by adding incremental small vol-
umes of solvent until all crystals had been dissolved (Table 1). We found Vx-770 extremely soluble in
anhydrous dimethyl sulfoxide (DMSO) (S ~ 0.77 M), and reasonably soluble in 1-octanol (S ~ 3.9 mM)
and ethanol (S ~ 3.1 mM). However, even the smallest amounts that we could weigh out (~0.1 mg)
failed to dissolve in 1 liter of aqueous saline (pH = 7.1), as evident from clearly visible crystals even
after vigorous shaking for 24 hr, forcing us to take a different approach. To generate an aqueous
solution exactly saturated with Vx-770, a small aliquot of crystals was added to an aqueous saline
(pH = 7.1) and, after vigorous shaking for 24 hr, visible crystals were removed by repeated filtering
and microcrystals sedimented by centrifugation (Materials and methods). The resulting supernatant
(our ‘1x saturated’ stock solution) was then used both for determination of Vx-770 solubility
(Figure 1b–c), and for functional experiments (Figures 2–5). Vx-770 dissolved in 1-octanol at 1–4
mM showed clearly measurable light absorption with a peak at 311 nm (Figure 1b, blue spectra),
yielding a calibration line in the micromolar range (Figure 1c, blue dots and fitted straight line). For
our 1x saturated aqueous stock solution the absorbance spectrum was flat against the background
saline, but when we extracted it with 1-octanol at a volume ratio of 20:1, the extract showed clear
absortion (Figure 1b, red spectrum, ‘1st extract’), corresponding to a Vx-770 concentration of ~1.2
mM (Figure 2b). Repeated extraction of the aqueous stock with 1-octanol yielded a flat spectrum
(Figure 2a, green spectrum, ‘2nd extract’), confirming that all Vx-770 had been efficiently extracted
Table 1. Solubilities of Vx-770 in various solvents at 25˚C.
Solubilities were determined as described in detail in Materials and methods. *Aqueous saline with
composition described in Materials and methods.
Solvent S (mol/L)
water (pH=7.1)* 6.210-8
pentane 1.810-5
octane 2.610-3
ethanol 3.110-3
1-octanol 3.910-3
DMSO 7.710-1
DOI: https://doi.org/10.7554/eLife.46450.002
Csana´dy and To¨ro¨csik. eLife 2019;8:e46450. DOI: https://doi.org/10.7554/eLife.46450 2 of 18
Research article Structural Biology and Molecular Biophysics
in the first round. Considering that Vx-770 was concentrated 20-fold during the extraction proce-
dure, we conclude that the true aqueous solubility of Vx-770 at 25˚C is only ~60 nM (Saq(25˚C,
pH = 7.1)=62 ± 2 nM, n = 4), almost 200-fold lower than generally believed, and severalfold lower
even than its reported EC50 values for potentiation of various CFTR mutants (160–600 nM)
(Van Goor et al., 2014).
Figure 1. Determination of aqueous solubility for Vx-770. (a) Structural formula of Vx-770 and 3D surface rendering by Molinspiration (https://www.
molinspiration.com/cgi-bin/properties). Red arrows identify potentially deprotonatable groups. (b) Absorption (O.D.) spectra for 0, 1, 2, and 4 mM Vx-
770 dissolved in 1-octanol (blue spectra), and for two sequential 1-octanol extracts (20:1 volume ratio) of an aqueous saline saturated with Vx-770 (red
and green spectra). (c) Calibration curve of O.D. at 311 nm for Vx-770 in 1-octanol (blue dots (mean ± S.E.M. from 3 measurements) and linear
regression line), and quantification of [Vx-770] in the first 1-octanol extract (red dot).
DOI: https://doi.org/10.7554/eLife.46450.003
Figure 2. CFTR current stimulation by Vx-770 is fully reversible. (a) Macroscopic WT CFTR channel current, elicited
in an inside-out patch by exposure to 2 mM ATP (gray bar), is enhanced ~4-fold by application of a 1x saturated
(~62 nM) Vx-770 solution (red bar), and relaxes back to its pre-drug level following drug removal. Red line is a
fitted exponential with time constant (t) indicated. Channels had been pre-phosphorylated by an ~1-min exposure
to 300 nM PKA catalytic subunit, membrane potential is -40 mV. (b) 1-min segments of recording from a single
pre-phosphorylated WT CFTR channel gating in 2 mM ATP before drug exposure (top), in the presence of 0.05x
saturated (~3 nM) Vx-770 (center; segment starts ~4 min after drug addition), and long after Vx-770 removal
(bottom, segment starts ~9 min after drug removal). (c) Open probabilities (left), opening rates (center), and
closing rates (right) of single pre-phosphorylated WT CFTR channels gating in 2 mM ATP, before (dark gray bars),
during (red bars), and after (light gray bars) exposure to 0.05x saturated (~3 nM) Vx-770. Bars show mean ± S.E.M.
from 9 experiments.
DOI: https://doi.org/10.7554/eLife.46450.004
Csana´dy and To¨ro¨csik. eLife 2019;8:e46450. DOI: https://doi.org/10.7554/eLife.46450 3 of 18
Research article Structural Biology and Molecular Biophysics
CFTR Channel Stimulation by Vx-770 is fully reversible
Because in all published in vitro studies Vx-770 was applied at concentrations ranging from 100 nM
to 10 mM (Cui and McCarty, 2015; Yeh et al., 2015; Yeh et al., 2017; Langron et al., 2018;
Liu and Dawson, 2014; Van Goor et al., 2009; Van Goor et al., 2014; Yu et al., 2012;
Wang et al., 2014; Wang et al., 2018; DeStefano et al., 2018; Jih and Hwang, 2013; Lin et al.,
2016; Kopeikin et al., 2014), our present solubility estimate indicates that Vx-770 effects have so
far been characterized only at supersaturated concentrations. We reasoned that this circumstance
might explain some of the puzzling features of the drug, such as CFTR channel inactivation observed
in some cases (Cholon et al., 2014), as well as apparent irreversibility of drug effects (Jih and
Hwang, 2013; Lin et al., 2016; Yeh et al., 2015; Yeh et al., 2017; Wang et al., 2014; Wang et al.,
2018). To investigate stability and reversibility of Vx-770 effects in a concentration range that can be
achieved in the human body during oral drug administration, we tested the effects of our 1x satu-
rated Vx-770 solution and its dilutions in inside-out patches excised from Xenopus laevis oocytes
expressing WT or mutant human CFTR channels.
Indeed, in inside-out patches (Figure 2a), application of our 1x saturated Vx-770 solution (red
bar) to prephosphorylated WT CFTR channels opened by 2 mM ATP (gray bar) caused rapid robust
(~4 fold) current stimulation which lasted as long as the drug was applied. However, upon drug
removal the current readily declined back to its pre-drug value (time constant t ~2 min, Figure 2a,
red fit line), demonstrating full reversibility of Vx-770 effects. In single-channel recordings
(Figure 2b), even a 20-fold dilution of our 1x saturated Vx-770 stock stimulated open probability of
WT CFTR to a comparable level, by ~4 fold (Figure 2c, left). Stimulation of open probability was due
to acceleration of channel opening and slowing of channel closure (Figure 2b, top and center trace;
Figure 3. Vx-770 stimulates CFTR currents already at subnanomolar concentrations. (a-b) Macroscopic WT CFTR currents elicited by 2 mM ATP are
reversibly stimulated by exposure (red and brown bars) to indicated concentrations of Vx-770, diluted either from a 1x saturated aqueous stock (a) or
from a 10-mM stock dissolved in DMSO (b). (c) Fractional stimulation of WT CFTR currents by Vx-770 diluted from a 1x saturated aqueous (red symbols
and abscissa), or a DMSO-based (brown symbols and abscissa), stock. Abscissae are aligned based on the aqueous solubility of Vx-770 (~62 nM). (d–e)
Quasi-macroscopic currents of prephosphorylated G551D (d) and DF508 (e) CFTR channels in 2 mM ATP are reversibly stimulated by exposure (red
bars) to indicated concentrations of Vx-770, diluted from a 1x saturated aqueous stock. Deactivation time courses following drug removal are fitted with
single exponentials (red lines). (f) Fractional stimulation of G551D (blue symbols) and DF508 (green symbols) CFTR currents by Vx-770 diluted from a 1x
saturated aqueous stock; abscissa has been calibrated. Symbols in (c) and (f) show mean ± S.E.M. from 3-13 experiments, solid curves are fits to an
adapted Hill equation (Materials and methods) with parameters plotted. Hill coefficients were 1.31±0.65 and 1.32±0.47 for WT in Vx-770 or Vx-770/
DMSO, 1.12±0.07 for DF508, and 1.22±0.10 for G551D CFTR.
DOI: https://doi.org/10.7554/eLife.46450.005
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Figure 2c, red vs. dark gray bars), consistent with previous studies in which the drug had been
applied at supersaturating concentrations (Kopeikin et al., 2014; Jih and Hwang, 2013). However,
in contrast to those earlier studies, the observed effects on channel gating were fully reversible fol-
lowing washout of the drug (Figure 2b, bottom trace; Figure 2c, light gray bars).
Vx-770 stimulates WT and mutant CFTR channels already at
subnanomolar concentrations
To estimate the true stimulatory potency of the drug, a series of dilutions of our 1x saturated Vx-770
stock was first tested on WT CFTR channels (Figure 3a, red bars). We observed robust stimulation
of WT CFTR currents by even a 100-fold dilution of our 1x saturated Vx-770 stock (Figure 3a, second
trace from left), suggesting a subnanomolar apparent affinity for the drug. Indeed, a dose response
curve (Figure 3c, red symbols), obtained by assuming [Vx-770]=62 nM in our 1x saturated stock (cf.,
Table 1), yielded a K0.5 of 0.47 ± 0.12 nM (Figure 3c, red fit line). As a control, a dose response rela-
tionship obtained by exposure of WT CFTR channels to known concentrations of Vx-770 (Figure 3b,
brown bars), obtained by sequential dilutions of a commercially available 10 mM DMSO-based Vx-
770 stock (Selleck Chemicals), yielded a K0.5 for current stimulation of 0.49 ± 0.15 nM (Figure 3c,
brown symbols and fit line), confirming our estimate of Vx-770 aqueous solubility. Thus, the apparent
K0.5 of Vx-770 for stimulation of WT CFTR is ~600 fold lower than previously reported (~300 nM
[Van Goor et al., 2014; Langron et al., 2018]).
Figure 4. Delayed activation by low nanomolar Vx-770 suggests multiple sequential slow steps in activation
process. (a) Stimulation of macroscopic WT CFTR currents in 2 mM ATP by exposure to a 1x (black trace; dark gray
and red bar) or an 0.01x (gray trace; light gray and purple bar) saturated aqueous solution of Vx-770. Current
amplitudes have been rescaled by their pre-drug values, and superimposed traces are shown synchronized to the
time point of drug addition. Sigmoidal activation time courses are fitted (blue lines) by a sequential three-step
mechanism, and apparent activation time constants (t*, see Materials and methods) are plotted. Deactivation time
courses are fitted (green lines) by single exponentials with time constants (t) indicated. (b–c) Overall rates of
current stimulation (1/ton*; b) and rates of deactivation (1/toff; c) in response to addition and removal, respectively,
of indicated concentrations of Vx-770. Mean ± S.E.M. from 5-7 experiments. (d) (Top) Continuous ~16-min
recording from a single prephosphorylated WT CFTR channel gating in 2 mM ATP (gray bar) and exposed for ~6
min to 0.05x saturated (~3 nM) Vx-770 (red bar). (Center) Open probability calculated over sequential 46-s intervals
for the recording shown on top. Note sudden switch from low- (gray bars) to high-activity gating (red bars) ~3 min
after initiation of drug exposure, and a similarly sudden switch back to low-activity gating ~5 min after drug
removal. (Bottom) 1-min segments marked by green bars in the recording on top are shown at an expanded time
scale.
DOI: https://doi.org/10.7554/eLife.46450.006
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Figure 5. Model fitting of activation/deactivation time courses in response to cytosolic addition/removal of Vx-770. (a-d) Cartoon representation of
schemes with one (a, b) or two (c, d) drug binding sites, and one (a, c) or two (b, d) membrane compartments (cytoplasmic, bottom; extracellular, top).
(e) Fit parameters obtained from global fits of Schemes 3 (left column) and 4 (right column) to the data set shown in f. *Parameters kin and kout were
constrained through kin/kout = Doct/wat(pH=7.1) = 62580. Parameters Kd;mem, K0.5;mem, and K0.5;aq were calculated from the fit parameters as described in
Figure 5 continued on next page
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When tested on patches containing G551D (Figure 3d) or DF508 (Figure 3e) CFTR channels,
robust current stimulation was also observed already at subnanomolar concentrations. For both
mutants maximal current stimulation was 11–12-fold with a K0.5 of ~1.5 nM (Figure 3f, blue and
green symbols and fit lines), and was fully reversible with a time constant of ~2 min (Figure 3d–e, fit-
ted lines). Thus, the true potency of Vx-770 for G551D CFTR is ~200 fold higher, and for DF508
CFTR 20–300-fold higher, than previously reported (Van Goor et al., 2009; Yu et al., 2012;
Van Goor et al., 2014; Langron et al., 2017).
Delayed channel activation by low concentrations of Vx-770 suggests
multiple slow steps in the activation pathway
The kinetics of current deactivation following Vx-770 wash-off was well fitted assuming a single rate-
limiting step (Figure 4a, green single-exponential fit lines and time constants t). In contrast, the acti-
vation time course upon drug exposure was clearly sigmoidal, suggesting the presence of multiple
sequential slow steps in the activation pathway. Indeed, at least three sequential concentration-
dependent slow steps were required to obtain an adequate fit (Figure 4a, blue fit lines). In particu-
lar, at subnanomolar/low nanomolar aqueous drug concentrations current stimulation started off
with a marked delay of up to ~1 min (Figure 4a, gray trace), consistent with slow drug accumulation
in the membrane being required for CFTR potentiation (Jih and Hwang, 2013). As expected, deacti-
vation rate (1/toff) was independent of drug concentration (Figure 4c), whereas the overall rate of
activation (1/ton*, see Materials and methods) became faster at higher concentrations (Figure 4b).
At a single-channel level both application and removal of low concentrations of Vx-770 (Figure 4d,
top, red bar) caused abrupt changes in channel open probability, but with a marked delay
(Figure 4d, stability plot, red vs. gray bars; bottom, expanded current segments).
Time courses of channel activation and deactivation by Vx-770 are well
fitted by a model with two intramembrane drug binding sites
We next attempted to interpret the observed complex kinetics of the drug effects in terms of various
molecular models (Figure 5a–d), by performing global fits of each model (Figure 5f, colored lines)
to the ensemble of four experimentally observed current time courses: activation and deactivation
upon addition and removal of 0.01x saturated (Figure 5f, gray trace) and 1x saturated (Figure 5f,
black trace) Vx-770. To reduce the number of free parameters in the considered models, the equilib-
rium ratio of membrane-dissolved and aqueous concentrations of Vx-770 (i.e., the ratio kin/kout,
Figure 5a–d) was fixed to its measured octanol/water distribution coefficient (Doct/wat(pH=7.1)=62580,
logD = 4.8, cf., Table 1), a well-established approximator of membrane/water distribution for a large
number of diverse drugs with logD values ranging between 1 and 5.5 (Gobas et al., 1988).
One slow step involved in both activation and deactivation might be drug equilibration between
the membrane and the aqueous phase (described by rate constants kin and kout), and/or binding/
unbinding between membrane-dissolved drug and the channel protein (described by rate constants
kon’ and koff). However, a simple two-step mechanism (Scheme 1, Figure 5a) was clearly insufficient
to account for the marked delay in channel activation observed at low drug concentrations
(Figure 5f, green fit lines).
Given that in inside-out patch-clamp experiments Vx-770 enters the membrane only from the
cytosolic side during drug application, whereas it can leave the membrane on both sides following
drug wash-off, one additional slow step specific to the activation process could be slow flipping of
the drug into the outer membrane leaflet, if the binding site on the CFTR protein resided on the
Figure 5 continued
Materials and methods. (f) Pair of normalized macroscopic WT CFTR current activation/deactivation time courses recorded in response to cytosolic
addition/removal of 0.01x saturated (gray trace) and 1x saturated (black trace) concentrations of Vx-770 (replotted from Figure 4a), and ensemble fits
by the models in a–d (colored lines; green, Scheme 1, pink, Scheme 2, blue, Scheme 3, red, Scheme 4). See also Figure 5—figure supplement 1.
DOI: https://doi.org/10.7554/eLife.46450.007
The following figure supplement is available for figure 5:
Figure supplement 1. Scheme 2 adequately fits individual on- and off- time courses but not the global data set.
DOI: https://doi.org/10.7554/eLife.46450.008
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extracellular half of its transmembrane region (Scheme 2, Figure 5b, flip-flop rates are assumed sym-
metrical (kflip)). However, whereas such a two-compartment membrane model provides sufficient
flexibility for perfectly fitting any individual, highly sigmoidal, on- time course (Figure 5—figure sup-
plement 1, solid pink fit line), or even for reasonably describing an entire on-off current time course
for any given drug concentration (Figure 5—figure supplement 1, solid red and blue fit lines), the
ensemble fit of the entire data set by Scheme 2 (Figure 5f, pink fit lines) was barely improved rela-
tive to the fit by Scheme 1 (Figure 5f, green fit lines), despite the introduction of an additional free
parameter (kflip).
An alternative mechanism that could explain delayed activation by the drug is the presence of
multiple drug binding sites, all of which must be occupied to switch the channel to a high open
probability state. Of note, a recent study suggested two potential binding sites for Vx-770 in the
transmembrane domains of CFTR (Yeh et al., 2019). We therefore evaluated a simplistic model
which postulates independent drug binding to two sites, with identical affinities, but a substantial
change in open probability (from Po;bas to Po;max) only for diliganded channels (Scheme 3,
Figure 5c). Interestingly, although it contains no additional free parameters relative to Scheme 1,
Scheme 3 provided a dramatically improved ensemble fit, yielding a single set of rate constants
(Figure 5e, left) that can reasonably account for the current activation and deactivation time courses
observed in response to addition and removal of Vx-770, over a 100-fold concentration range
(Figure 5f, blue fit lines).
Finally, assuming a two-compartment membrane and two drug-binding sites, both accessible
from the outer leaflet (Scheme 4, Figure 5d), afforded a further small improvement (Figure 5f, red
fit lines) relative to Scheme 3, albeit at the expense of an extra free parameter (Figure 5e, right).
pH- and temperature dependence of Vx-770 solubility
The pH of our standard bath solution (7.1) resembles intracellular pH, but extracellular pH in the
human body is typically higher (~7.4). This transmembrane pH gradient might influence the distribu-
tion of Vx-770 in the body, as the drug contains two potentially deprotonatable groups (Figure 1a,
red arrows), and the negative charge acquired upon deprotonation is expected to greatly enhance
its aqueous solubility. Because the computationally (Chemaxon) predicted strongest acidic pKa value
varies between 6.57 and 8.66, depending on the method of prediction, we measured Vx-770 solubil-
ity in our standard bath solution after adjusting its pH to 7.4 (see Materials and methods). From
three independent measurements we obtained an estimate of Saq(25˚C, pH = 7.4) = 50 ± 1 nM
(mean ± S.E.M.), which is not larger than that obtained for pH = 7.1, the small difference likely
reflecting experimental limitations. This finding suggests that the strongest acidic pKa value of the
drug is substantially higher than 7.4, and so the uncharged, fully protonated form remains the domi-
nant microspecies in the entire physiological pH range. The corollary is that the aqueous solubility of
the drug is similar in the cytosol and the extracellular space.
As a further parameter of clinical interest, we also determined the aqueous solubility of Vx-770 at
body temperature (pH = 7.1). Consistent with reports for other hydrophobic drugs (Baena et al.,
2004; Garzo´n and Martı´nez, 2004; Mota et al., 2009), Vx-770 aqueous solubility at 37˚C was ~2
fold higher compared to that at 25˚C, three independent measurements yielding an estimate of
Saq(37˚C, pH = 7.1) = 138 ± 1 nM (mean ± S.E.M.). The standard enthalpy of solution, estimated
from the solubilities at 37˚C vs. 25˚C, is DHosol = +51.2 kJ/mol, and the standard free energy of solu-
tion at 25˚C is DGosol = +41.1 kJ/mol (Materials and methods). Thus, the thermodynamic explanation
for the extremely low aqueous solubility of Vx-770 is that the entropy increase (TDSosol = +10.1 kJ/
mol at 25˚C) associated with the solution process is too small to compensate for the large increase in
enthalpy, likely caused by the disruption of hydrogen bonds between water molecules.
Discussion
The discovery of the CFTR potentiator Vx-770 has caused a major change in the therapy of CF
patients, allowing to address for the first time the root cause of the disease. To date, thousands of
patients are taking the drug on a daily basis, which warrants that studying its mechanisms will remain
in the center of research efforts for years to come. As for all drugs approved for clinical use, exten-
sive clinical studies have established its pharmacokinetic profile and safety features, and quantified
its clinical effects. On the other hand, many of its basic physicochemical properties, as well as its
Csana´dy and To¨ro¨csik. eLife 2019;8:e46450. DOI: https://doi.org/10.7554/eLife.46450 8 of 18
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precise molecular mechanism of action, remain to be established. Vx-770 shows good oral bioavail-
ability, and peak plasma concentrations of ~4 mM, and >10 mM, respectively, have been measured in
patients receiving twice daily 150 mg (therapeutic) or 450 mg (supratherapeutic) doses (FDA report
by Vertex Pharmaceuticals Incorporated, https://www.accessdata.fda.gov/drugsatfda_docs/nda/
2012/203188Orig1s000OtherRedt.pdf). In the plasma, most of the drug is bound to plasma proteins,
which are important for its pharmacokinetics, as they tremendously increase the drug transport
capacity of the blood and therefore oral bioavailability, and act as a drug buffer system that replen-
ishes the free drug pool during the time course of its elimination from the body. On the other hand,
cell membranes are at equilibrium with free dissolved Vx-770, not with the protein-bound drug.
Therefore, in a living organism the target cell membranes will accumulate Vx-770 only to an extent
that is at equilibrium with free dissolved Vx-770 (in the extracellular fluid and/or in the cytosol). In
the present study, we have established an upper limit for the latter parameter, which thus deter-
mines the maximal possible drug concentration achievable in target cell membranes. We have fur-
ther shown that Vx-770 solubility is independent of pH in the physiological pH range, which
implicitly indicates that its smallest acidic pKa value is far higher than 7.4, and that the dominant
microspecies is therefore the fully protonated uncharged form. Consequently, the distribution of the
drug between the cytosol and extracellular space is unaffected by the transmembrane pH gradient
and the membrane potential.
Because in all published in vitro studies Vx-770 was applied at concentrations ranging from 100
nM to 10 mM (Cui and McCarty, 2015; Yeh et al., 2015; Yeh et al., 2017; Langron et al., 2018;
Liu and Dawson, 2014; Van Goor et al., 2009; Van Goor et al., 2014; Yu et al., 2012;
Wang et al., 2014; Wang et al., 2018; DeStefano et al., 2018; Jih and Hwang, 2013; Lin et al.,
2016; Kopeikin et al., 2014), our present solubility estimate (50–62 nM at 25˚C, 138 nM at 37˚C)
indicates that Vx-770 effects have so far been characterized only at highly (up to ~200 fold) supersat-
urated concentrations, that also exceed (by up to ~100 fold) the highest free drug concentrations
that can be ever attained at 37˚C, that is in the human body using oral drug administration. This cir-
cumstance readily explains some of the reported puzzling features of the drug. For instance, when
superfusing a patch with a supersaturated aqueous solution of Vx-770, the drug will accumulate at
supersatured concentrations even in the membrane, likely resulting in the formation, and time-
dependent growth, of crystalline precipitates within the bilayer. Such precipitates might have con-
tributed to CFTR channel inactivation observed in some studies (Cholon et al., 2014). Moreover, fol-
lowing removal of Vx-770 from the aqueous perfusate, the membrane-dissolved drug pool might be
replenished from such intra-membrane crystalline precipitates as long as the crystals last (which will
depend on the degree of supersaturation of the applied aqueous test solution, and on exposure
time), explaining the reported irreversibility of drug effects (Jih and Hwang, 2013; Lin et al., 2016;
Yeh et al., 2015; Yeh et al., 2017; Wang et al., 2014; Wang et al., 2018). Indeed, we show here
that the potentiating effect of Vx-770 on CFTR is fully reversible (Figures 2–3), as long as supersatu-
rating drug concentrations are avoided.
Based on our data (Figure 3c,f), the apparent affinity of Vx-770 for WT CFTR is 600-fold, for
G551D CFTR ~200 fold, and for DF508 CFTR 20–300-fold higher than previously reported. One likely
explanation for the discrepancy between previous estimates of Vx-770 potencies and those obtained
here is the use of static recording chambers in the previous studies as opposed to the continuous
superfusion employed here. The octanol/water distribution coefficient of Vx-770 is ~60000 (cf.,
Table 1). Thus, if cellular membranes constitute as little as ~0.17% of the total assay volume,
then ~99% of the drug will accumulate in those membranes and its free aqueous concentration will
remain only ~1% of the total. Furthermore, when applied at supersaturated concentrations, large
fractions of the drug will precipitate onto the walls of the recording chamber.
Precise molecular interpretation of the complex kinetic steps involved in drug-activation
(Figure 4a) will clearly require much further work, including definitive localization of the
drug binding site(s). However, a simple kinetic model which postulates two independent and similar-
affinity binding sites, with potentiation requiring simultaneous binding of two drug molecules
(Scheme 3, Figure 5c), afforded a remarkably good description of current activation/deactivation
time courses over a broad range of applied drug concentrations (Figure 5f, blue fit lines). The rea-
sonable fit of an ensemble of four highly non-linear curves by a single set of only four free parame-
ters (kout, kon’, koff, and Po;max/Po;bas; with kin constrained to kin = koutDoct/wat(pH=7.1)) strongly argues
in favor of this model. Recently, in silico docking to high-resolution CFTR structures of the
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potentiator GLPG-1837, a drug known to compete with Vx-770 for CFTR activation (Yeh et al.,
2017), identified potential drug binding sites in CFTR’s transmembrane domains (Yeh et al., 2019).
Interestingly, mutations introduced into either of two putative sites strongly impaired potentiation
by both GLPG-1837 and Vx-770 (Yeh et al., 2019). However, because dose response curves for
GLPG-1837 activation are fitted with Hill coefficients close to unity, the authors were uncertain how
to interpret those findings. They suggested that either both sites are true drug binding sites, or only
one site is a true binding site, while mutations at the other site allosterically affect the structure of
the true site. Of note, Scheme 3 predicts an apparent Hill slope of only ~1.17 (see Materials and
methods) which is consistent with the values obtained both for GLPG-1837 by Yeh and colleagues,
and for Vx-770 in the present study (Figure 3). We therefore consider Scheme 3 the best current
working model for describing the molecular mechanism of CFTR potentiation by Vx-770. Average
rate constants obtained from ensemble fits to three pairs of current traces, such as those in
Figure 5f, are summarized in Table 2 (left).
Considering that measured diffusion coefficients of small molecules within a lipid bilayer fall in
the range of 10 8 to 10 7 cm2/s (Ladha et al., 1996; Macha´nˇ and Hof, 2010), the apparent second-
order on-rates (kon’) of Vx-770 obtained from the fits to Scheme 3 are several orders of magnitude
slower than expected for diffusion-limited binding of membrane-dissolved drug molecules to the
CFTR protein. One possible explanation for this slow apparent on-rate could be that the drug
remains associated with the polar surface of the bilayer, consistent with the hydrogen bonding capa-
bility of its five polar groups (Figure 1a). In that case, if the drug binding sites on the CFTR protein
are located in the outer leaflet of the membrane, drug binding could be rate limited by slow flipping
of the drug from the inner to the outer leaflet. Such a scenario could be consistent with the location
of the two binding sites proposed by Yeh and colleagues, which are closer to the extracellular than
to the intracellular membrane surface (Yeh et al., 2019). However, despite the introduction of an
additional free parameter (kflip), a two-compartment membrane model (Scheme 4, Figure 5d) only
marginally improved the fits (Figure 5f, red fit lines). Thus, unless molecular dynamics simulations
provide further support for such a model, we do not consider Scheme 4 (Figure 5d, Table 2, right) a
substantially better working model compared to Scheme 3. An alternative possible explanation for
the drug’s slow apparent on-rate could be diffusion-limited loose binding followed by a slower
induced fit conformational change.
Two common mechanistic conclusions suggested by the Scheme-3 and Scheme-4 fits are that (i)
two drug molecules need to bind to the channel protein to achieve potentiation, and that (ii) the
Table 2. Model fit parameters for Schemes 3 and 4.
Average fit parameters (mean ± S.E.M.) obtained from global fits of Schemes 3 (left column) and 4
(right column) to three pairs of macroscopic WT CFTR current activation/deactivation time courses
recorded in response to addition/removal of 0.01x saturated and 1x saturated concentrations of Vx-
770 to the cytosolic (bath) solution. * Parameters kin and kout were constrained through kin/kout = Doct/
wat(pH=7.1) = 62580. ** Parameters Kd;mem, K0.5;mem, and K0.5;aq were calculated from the fit parameters
as described in Materials and methods.
Scheme 3 4
kin (s
-1)* 4034 ± 464 9794 ± 531
kout (s
-1)* 0.06446 ± 0.00742 0.1565 ± 0.0085
kon’ (M
-1s-1) 870.3 ± 104.0 3703 ± 627
koff (s
-1) 0.007451 ± 0.000871 0.01075 ± 0.00009
kflip (s
-1) - 0.04408 ± 0.00583
Po;max/Po;bas 3.935 ± 0.001 3.996 ± 0.007
Kd;mem (mM)** 8.751 ± 1.160 3.106 ± 0.605
K0.5;mem (mM)** 21.13 ± 2.80 7.498 ± 1.460
K0.5;aq (nM)** 0.6752 ± 0.0895 0.6690 ± 0.0955
DOI: https://doi.org/10.7554/eLife.46450.009
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slow channel deactivation time course following drug removal reflects the slow dissociation rate of
the bound drug from the protein (koff), rather than slow washout of unbound drug molecules from
the membrane (kout).
In conclusion, we have established the basic physicochemical properties of Vx-770, including its
solubility profile and the thermodynamic parameters of the aqueous solution process. We have fur-
ther determined its true potency towards WT, G551D, and DF508 CFTR, which is orders of magni-
tude higher than previously believed. Finally, we have identified a kinetic model which is suitable to
describe its molecular mechanism. Our findings provide a solid framework to guide extensive current
research efforts aimed at studying Vx-770 effects in vitro. A clinically relevant aspect of our findings
is that half-maximal CFTR potentiation is achieved already by an ~100 fold dilution of a saturated Vx-
770 solution. Thus, it might be worth testing whether drug doses lower than the currently approved
dosage regimes are equally beneficial to CF patients, as this could reduce treatment costs that are
currently ~300000 USD/patient/year.
Materials and methods
Key resources table
Reagent type
(species)
or resource Designation
Source
or reference Identifiers
Additional
information
Biological sample
(Xenopus laevis)
Xenopus
laevis oocytes
African Reptile Park RRID: NXR_0.0080 mandyvorster@
xsinet.co.za
Commercial
assay or kit
HiSpeed
Plasmid Midi Kit
Qiagen 12643
Commercial
assay or kit
QuickChange
II Mutagenesis Kit
Agilent Technologies 200524–5
Commercial
assay or kit
mMESSAGE mMACHINE
T7 Transcription Kit
ThermoFisher AM1344
Chemical
compound, drug
Collagenase
type II
Gibco 17107–0125
Chemical
compound, drug
Adenosine
50-triphosphoribose magnesium
(ATP)
Sigma-Aldrich A9187
Chemical
compound, drug
Protein kinase
A catalytic
subunit, bovine
Sigma-Aldrich P2645
Chemical
compound, drug
Vx-770 (solid) Selleck Chemicals S1144
Chemical
compound, drug
Vx-770
(10 mM in
DMSO)
Selleck Chemicals S1144
Software,
algorithm
Pclamp9 Molecular Devices RRID: SCR_011323
Determination of Vx-770 solubility profile
Crystalline Vx-770 (purity 99.58% by HPLC) was purchased from Selleck Chemicals (Houston, TX,
USA). Solubilities (S) at 25˚C in anhydrous dimethyl sulfoxide (DMSO) (S ~ 0.77 M), 1-octanol (S ~ 3.9
mM), ethanol (S ~ 3.1 mM), octane (S ~ 2.6 mM), and pentane (S ~ 18 mM) were determined by
weighing out a small amount (1–2 mg) of crystals on an analytical balance (Kern ABJ), and adding
incremental small volumes of solvent, followed by mixing, until all crystals had been dissolved. How-
ever, even the smallest amount of Vx-770 that we could weigh out (~0.1 mg, obtained by manually
dividing an ~0.5 mg aliqout into five comparable heaps under a stereomicroscope) failed to dissolve
in 1 liter of water, as evident from clearly visible crystals even after vigorous shaking (200 RPM, New
Brunswick Excella E24) for 24 hr at 25˚C.
To obtain an aqueous solution (pH = 7.1) exactly saturated with Vx-770 (our ‘1x saturated’ stock),
a small aliquot of Vx-770 crystals (~0.1 mg) was added to 250 ml of our standard bath solution (in
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mM: 134 NMDG-Cl, 2 MgCl2, 5 HEPES, 0.5 EGTA, pH = 7.1 with NMDG), and the solution was
shaken for 24 hr at 25˚C at 200 RPM (New Brunswick Excella E24). Remaining, clearly visible, macro-
crystals were removed by filtering the solution twice through an 0.22 mm pore size filter (Millipore
Durapore Steritop + Stericup, Merck KGaA, Darmstadt, Germany). To sediment invisible microcrys-
tals, the filtrate was centrifuged at 7200 RCF for 1 hr in 50 ml conical tubes, and the supernatant
carefully removed, leaving the last ~1 ml behind. The resulting cleared filtrate was stored and used
as a stock solution for all subsequent studies.
The concentration of Vx-770 in the 1x saturated stock was determined by spectrophotometry
(NanoPhotometer P300, Implen GmbH). Vx-770 dissolved in 1-octanol shows strong absorption with
a peak at 311 nm. To obtain a calibration curve, Vx-770 (from a commercial 10 mM stock dissolved
in DMSO, purchased from Selleck Chemicals) was diluted into 1-octanol (saturated with water) to
final concentrations of 1, 2, 4, 8, and 16 mM. Absorption spectra were measured in a 1 ml quartz
cuvette against 1-octanol (saturated with water) as a blank (Figure 1b, blue spectra). Peak absorp-
tion at 311 nm was linear with Vx-770 concentration across the entire range (the 0–4 mM range is
shown in Figure 1c, blue dots). To extract Vx-770 from the 1x saturated aqueous stock, two 15 ml
conical tubes, each containing 14 ml of the 1x aqueous stock plus 0.7 ml 1-octanol, were vortexed
for 1 min, and then centrifuged at 7200 RCF for 30 min. Approximately 2  0.6 ml of the 1-octanol
phase was recovered, pooled, and its absorption spectrum measured in a 1 ml quartz cuvette
against 1-octanol (saturated with water) as a blank (Figure 1b, red spectrum). To extract the remain-
ing aqueous phase for a second time, the remnants of the 1-octanol phase were carefully discarded
from both conical tubes, and 12.5 ml of the remaining aqueous phase (removed by inserting the
pipette tip well below the surface) was transferred into two clean conical tubes. The extraction was
then repeated using 2  0.625 ml 1-octanol, from which 2x ~ 0.5 ml was recovered, pooled, and
assayed for optical density (Figure 1b, green spectrum).
Aqueous solubility at pH = 7.4 (25˚C) was measured as described above for pH = 7.1, but starting
from a standard bath solution with pH adjusted to 7.4 using NMDG. The spectrophotometric calibra-
tion curve was obtained in this case using 1, 2, 4, 8, and 16 mM Vx-770 dissolved in 1-octanol (satu-
rated with the pH = 7.4 bath solution). The obtained calibration curve was identical to that shown in
Figure 1b–c (i.e., Vx-770 fluorescence was insensitive to whether it was dissolved in 1-octanol satu-
rated with water (as in Figure 1), or with saline buffered to either pH = 7.1, 7.3, or 7.4).
To determine aqueous solubility at 37˚C (pH = 7.1), an aliquot of standard bath solution was
heated to 37˚C in a water bath. Because the pKa of HEPES is temperature dependent, heating to 37˚
C caused a decrease in pH by 0.17 units. The pH of the solution was therefore readjusted to 7.1 at
37˚C using NMDG. To obtain a 1x saturated solution at 37˚C, overnight shaking with Vx-770 crystals,
subsequent 2x filtering, and centrifugation were all perfomed at 37˚C. To measure Vx-770 concentra-
tion in the 1x saturated stock solution, 0.7 ml 1-octanol was added to 14 ml aliquots of the stock at
37˚C, the tubes were vortexed for 1 min, and the subsequent steps of the 1-octanol extraction pro-
cedure, as well as the spectrophotometric determination, were performed at room temperature, as
described above.
Estimation of thermodynamic parameters of the Vx-770 aqueous
solution process
The standard enthalpy of solution was calculated as DHosol = ((RT1T2)/(T2 T1))ln(S(T2)/S(T1)), where
R = 8.31 Jmol 1K 1, T1 = 298 K (25˚C), T2 = 310 K (37˚C), and S(T1) and S(T2) are the measured aque-
ous solubilities of Vx-770 at the respective temperatures (pH = 7.1). The standard free energy of
solution at T = 298 K (25˚C) was calculated as DGosol =  RTln(S(T)).
Molecular biology
The G551D and DF508 mutations were introduced into pGEMHE-CFTR using the QuikChange Kit
(Agilent, Santa Clara, CA, USA), and confirmed by automated sequencing; cDNA was purified
(HiSpeed Plasmid Midi Kit, Qiagen), transcribed in vitro (mMessage T7 Kit, ThermoFisher Scientific,
Waltham, MA USA) and cRNA stored at  80˚C.
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Isolation and injection of Xenopus laevis oocytes
Oocytes were extracted from anaesthethized adult female Xenopus laevis (RRID: NXR_0.0080) fol-
lowing Institutional Animal Care Committee guidelines, isolated using collagenase treatment (Gibco,
Collagenase type II), injected with 0.1–10 ng cRNA in a fixed 50 nl volume, and stored at 18˚C in a
modified frog Ringer’s solution (in mM: 82 NaCl, 2 KCl, 1 MgCl2, and 5 HEPES, pH 7.5 with NaOH)
supplemented with 1.8 mM CaCl2 and 50 mg/ml gentamycin. Current recordings were obtained 1–3
days after injection.
Excised inside-out patch recording
Patch pipette solution contained (in mM): 136 NMDG-Cl, 2 MgCl2, 5 HEPES, pH = 7.4 with NMDG.
Bath solution contained (in mM): 134 NMDG-Cl, 2 MgCl2, 5 HEPES, 0.5 EGTA, pH = 7.1 with
NMDG. MgATP (2 mM) was added from a 400 mM aqueous stock solution (pH = 7.1 with NMDG).
Before each experiment 300 nM catalytic subunit of PKA (Sigma-Aldrich Kft., Budapest, Hungary)
was applied for ~1 min to phosphorylate CFTR channels. Vx-770 (Selleck Chemicals) was diluted into
the bath solution either from a ‘1x saturated’ aqueous stock solution (see above, concentration ~62
nM), or from a commercially obtained 10 mM stock dissolved in DMSO (Selleck Chemicals). Follow-
ing patch excision the patch pipette was moved into a flow chamber, and recordings were done
under continuous superfusion of the cytosolic patch surface. Solution compositions were exchanged
using computer-driven electronic valves (solution exchange time constant <50 ms). After each
recording day perfusion tubings were extensively washed with distilled water. Although supersatu-
rated solutions of Vx-770 were not employed here, any perfusion tubing that had ever been in con-
tact with a given concentration of Vx-770 was subsequently used only for solutions that contained
the same, or higher, concentrations of the drug. After every 5–6 experimental days the entire perfu-
sion system was replaced. Currents were recorded at 25˚C, at a membrane potential of  40 mV, dig-
itized at 10 kHz, Gaussian-filtered at 2 kHz, and recorded to disk (Axopatch 200B, Digidata 1322A,
Pclamp9 (Molecular Devices, RRID: SCR_011323)). For display purposes, currents are shown filtered
at 10 Hz and sampled at 20 Hz, and expanded single-channel traces (Figure 2b, Figure 4d) are
shown filtered at 50 Hz and sampled at 250 Hz.
Analysis of macroscopic current recordings
Vx-770 was applied after currents elicited by 2 mM ATP had stabilized. To allow for full development
of its potentiator effect, Vx-770 was superfused until the current reached steady state which, for low
nanomolar Vx-770, required up to 5–6 min. After full stimulation, Vx-770 was washed off for at least
5 min to allow the current to decline to a post-drug steady state. Fractional current stimulation by
Vx-770 (I/Icontrol) was calculated as the mean steady current in the presence of the drug, divided by
the average of the pre- and post-drug mean steady currents. Dose response curves (Figure 3c,f)
were least-squares fitted to the modified Hill equation I/Icontrol=(K0.5
n+(Imax/Icontrol)[Vx-770]
n)/
(K0.5
n+[Vx-770]n), with Imax/Icontrol, K0.5, and n as free parameters.
To obtain apparent deactivation rates, current decay time courses following Vx-770 removal were
fitted by single exponentials using least squares, and deactivation rates defined as the inverse of the
decay time constant (1/toff; Figure 4c). To obtain apparent activation rates, current activation time
courses upon Vx-770 addition were fitted to an empirical three-step kinetic scheme S1fiS2fiS3fiS4.
Compound states S1-S4 in this scheme are not interpreted as channel conformational states, but
rather as states of the entire system (aqueous solution +patch membrane leaflets + channels), and
could reflect various stages of drug distribution among those compartments. The open probability
(Po) of CFTR channels in compound states S1, S2, and S3 was fixed to the Po observed for single WT
CFTR channels under control conditions (~0.16; Figure 2c), whereas the Po for CFTR channels in
compound state S4, and transition rates k12, k23, and k34, were left free (Figure 4a). (Whereas this
simple irreversible scheme is clearly unsuitable to explain reversibility of drug effects, and does not
address the mechanism of the drug, it provided sufficient flexibility for a perfect fit of individual acti-
vation time courses.) Apparent activation time constants (ton*) were defined as T1/2/ln2, where T1/2 is
the time required for the current to cross the midpoint between its pre-activated and fully activated
amplitudes. Apparent activation rates were defined as 1/ton* (Figure 4b).
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Kinetic analysis of microscopic patches
Segments of current recording originating from 1 to 7 active channels were digitally filtered at 50
Hz, and idealized by half-amplitude threshold crossing. Steady-state open probabilities in 2 mM
ATP, before or during application of Vx-770 or after its removal (Figure 2c), were calculated from
the events lists as the time-average of the fraction of open channels. A closed-open-blocked (C-O-B)
kinetic scheme, which separates brief (~10 ms) flickery closures (to state B) from long (~1 s) interburst
closures (to state C), was fitted by maximum likelihood to the set of dwell-time histograms for all
conductance levels, to obtain microscopic transition rates rCO, rOC, rOB, and rBO, while accounting
for a fixed dead time of 6 ms (Csana´dy, 2000). The software is freely available upon request. Mean
burst (tb) and interburst (tib) durations were calculated as tb=(1/rOC)(1 + rOB/rBO) and tib=1/rCO, and
channel opening and closing rates (Figure 2c) defined as 1/tib and 1/tb, respectively. The stability
plot in Figure 4d was obtained by calculating open probability over sequential 46 s time windows.
Ensemble fitting of gating models to pairs of on-off current time
courses
The dynamic equations that describe the kinetic models depicted in Figure 5 are as follows:
Scheme 1
dx1(t)/dt = kinVc – 2koutx1(t) – kon’x1(t)x2(t) + koff(Ct–x2(t))
dx2(t)/dt = – kon’x1(t)x2(t) + koff(Ct–x2(t))
where x1(t) is the concentration of free Vx-770 in the membrane, x2(t) is the concentration of unli-
ganded drug binding sites (CFTR channels) in the membrane, Ct is the total concentration of
drug binding sites (CFTR channels) in the membrane, and Vc is the concentration of Vx-770 in the
cytosol.
Scheme 2
dx1(t)/dt = kinVc – (kout +kflip)x1(t) + kflipx2(t)
dx2(t)/dt = kflipx1(t) – (kout +kflip)x2(t) – kon’x2(t)x3(t) + koff(Ct–x3(t))
dx3(t)/dt = – kon’x2(t)x3(t) + koff(Ct–x3(t))
where x1(t) is the concentration of Vx-770 in the inner membrane leaflet, x2(t) is the concentration
of free Vx-770 in the outer membrane leaflet, x3(t) is the concentration of unliganded drug binding
sites (CFTR channels) in the outer membrane leaflet, Ct is the total concentration of drug binding
sites (CFTR channels) in the outer membrane leaflet, and Vc is the concentration of Vx-770 in the
cytosol.
Scheme 3
dx1(t)/dt = kinVc – 2koutx1(t) – kon’(2x2(t)+x3(t))x1(t) + koff(2(Ct–x2(t)–x3(t))+x3(t))
dx2(t)/dt = – 2kon’x1(t)x2(t) + koffx3(t)
dx3(t)/dt = 2kon’x1(t)x2(t) + 2koff(Ct–x2(t)–x3(t)) – (koff +kon’x1(t))x3(t)
where x1(t) is the concentration of free Vx-770 in the membrane, x2(t) is the concentration of unli-
ganded CFTR channels in the membrane, x3(t) is the concentration of monoliganded CFTR channels
in the membrane, Ct is the total concentration of CFTR channels in the membrane, and Vc is the con-
centration of Vx-770 in the cytosol.
Scheme 4
dx1(t)/dt = kinVc – (kout +kflip)x1(t) + kflipx2(t)
dx2(t)/dt = kflipx1(t) – (kout +kflip)x2(t) – kon’(2x3(t)+x4(t))x2(t) + koff(2(Ct–x3(t)–x4(t))+x4(t))
dx3(t)/dt = – 2kon’x2(t)x3(t) + koffx4(t)
dx4(t)/dt = 2kon’x2(t)x3(t) + 2koff(Ct–x3(t)–x4(t)) – (koff +kon’x2(t))x4(t)
where x1(t) is the concentration of Vx-770 in the inner membrane leaflet, x2(t) is the concentration
of free Vx-770 in the outer membrane leaflet, x3(t) is the concentration of unliganded CFTR channels
in the outer membrane leaflet, x4(t) is the concentration of monoliganded CFTR channels in the outer
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membrane leaflet, Ct is the total concentration of CFTR channels in the outer membrane leaflet, and
Vc is the concentration of Vx-770 in the cytosol.
To calculate the value of Ct, the total number of channels in the patch (N) was estimated by
assuming Po;bas=0.16 for prephosphorylated channels in ATP (cf., Figure 2c). For Schemes 1 and 3
the volume of the membrane patch was taken as 10 16 liter (assuming a macroscopic patch surface
area of ~4 mm2 increased by ~5 fold at a microscopic level due to the presence of microvilli (Das-
cal, 1987), and a membrane thickness of ~5 nm), and for Schemes 2 and 4 the volume of the outer
membrane leaflet was taken as 510 17 liter. Ct was then calculated as N/NA divided by the relevant
volume (NA, Avogadro’s number). (In control trials in which up to 5-fold larger/smaller fixed mem-
brane volumes were used, the fits showed little sensitivity to the choice of membrane volume, apart
from appropriate rescaling of the obtained values for kon’ and kflip.)
For the ensemble fitting, all experimental current traces were normalized to their steady-state val-
ues observed prior to exposure to Vx-770. Predicted normalized on- and off- current time courses
for each model were calculated from the above dynamic equations by solving for the time-depen-
dent evolution of the vector x, using a modified Euler’s method (Press, 1992). For the on- time
courses the initial values for all xi were set to zero, for the off- time courses the final x vector of the
preceding on- time course served as the initial vector while Vc was set to zero. The predicted time
course of the normalized current trace was then obtained as x2(t)/Ct + (1–x2(t)/Ct)(Po;max/Po;bas)
(Scheme 1), x3(t)/Ct + (1–x3(t)/Ct)(Po;max/Po;bas) (Scheme 2), (x2(t)+x3(t))/Ct + (1–(x2(t)+x3(t))/Ct)(Po;
max/Po;bas) (Scheme 3), and (x3(t)+x4(t))/Ct + (1–(x3(t)+x4(t))/Ct)(Po;max/Po;bas) (Scheme 4), respectively.
The sets of predicted normalized on-off time courses were fitted to the sets of normalized experi-
mental current traces by simple least squares, using a downhill simplex method for optimization
(Press, 1992).
Steady-state solutions of the models and calculation of predicted
apparent affinities
Under the conditions used here, that is upon prolonged exposure of the cytosolic face of the patch
to a constant concentration of Vx-770, with no Vx-770 present on the extracellular side, all four
kinetic models shown in Figure 5 predict relaxation of the system to a steady state. At steady state
there is a constant outward directed transmembrane flux of Vx-770, while its concentration remains
constant within the membrane (or membrane leaflets), and close to zero in the extracellular (pipette)
solution. (The volume of the pipette solution, on the order of 10 5 l, can be considered infinitely
large relative to the volume of the patch membrane). For Schemes 1 and 3, the steady-state mem-
brane concentration of the drug is Vm;¥=Vckin/(2kout). For Schemes 2 and 4, the steady-state drug
concentrations in the cytosolic and external membrane leaflets (Vmc;¥, Vme;¥), respectively, are given
by Vmc;¥=Vc(kin/kout)(kout +kflip)/(kout +2kflip) and Vme;¥=Vc(kin/kout)kflip/(kout +2kflip).
Once the drug concentrations in the various compartments have stabilized, the channel pool
approaches an equilibrium distribution between its available (unliganded, ligandbound, and, for
Schemes 3 and 4, diliganded) forms. The concentration-dependence of steady-state current activa-
tion reflects the concentration-dependence of the fractional occupancy of the monoliganded state
(Y1) for Schemes 1 and 2, but of the diliganded state (Y2) for Schemes 3 and 4. The latter are given
by Y1 = V¥/(Kd;mem +V¥) and Y2 = (V¥/(Kd;mem +V¥))
2, respectively, where Kd;mem = koff/kon’, and
V
¥
=Vm;¥ for Schemes 1 and 3, but V¥=Vme;¥ for Schemes 2 and 4. The midpoints of these predicted
concentration response curves (K0.5;mem), that is the drug concentrations in the target compartment
(membrane or external membrane leaflet) that cause half-maximal stimulation, are obtained as K0.5;
mem = Kd;mem for Schemes 1 and 2, but K0.5;mem = (1+H2)Kd;mem for Schemes 3 and 4. When plotted
using a logarithmic abscissa, the midpoint slope of the dose response curve for Schemes 3 and 4
corresponds to that of a Hill function with Hill coefficint nH = 2(2–H2). The apparent drug affinities
(K0.5;aq), that is the drug concentrations in the cytosolic solution that cause half-maximal stimulation,
are obtained as K0.5;aq = K0.5;mem/(kin/(2kout)) for Schemes 1 and 3, but K0.5;aq = K0.5;mem/((kin/kout)
kflip/(kout +2kflip)) for Schemes 2 and 4.
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Statistics
Data are presented as mean ± S.E.M from 3 to 13 independent measurements, as indicated in the
figure legends. Statistical significance was quantified using Student’s two-tailed t test, differences
are reported as not significant for p>0.05, and significant for p<0.05* or p<0.01**.
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